Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRDN Stock Forecast 2026-2027
$14.28
Current Price
$1.47B
Market Cap
Buy 16
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VRDN Price Targets
+250.1%
To High Target of $50.00
+120.6%
To Median Target of $31.50
+40.1%
To Low Target of $20.00
VRDN Price Momentum
-4.0%
1 Week Change
-47.1%
1 Month Change
+3.8%
1 Year Change
-54.1%
Year-to-Date Change
-58.4%
From 52W High of $34.29
+21.4%
From 52W Low of $11.76
📊 TOP ANALYST CALLS
Did VRDN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Viridian is one of their latest high-conviction picks.
Latest VRDN Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, VRDN has a bullish consensus with a median price target of $31.50 (ranging from $20.00 to $50.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $14.28, the median forecast implies a 120.6% upside. This outlook is supported by 16 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Yee at UBS, projecting a 250.1% upside. Conversely, the most conservative target is provided by Derek Archila at Wells Fargo, suggesting a 40.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRDN Analyst Ratings
16
Buy
1
Hold
0
Sell
VRDN Price Target Range
Low
$20.00
Average
$31.50
High
$50.00
Current: $14.28
Latest VRDN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRDN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $33.00 |
| Apr 8, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $31.00 |
| Apr 7, 2026 | Goldman Sachs | Richard Law | Buy | Maintains | $31.00 |
| Apr 7, 2026 | RBC Capital | Lisa Walter | Outperform | Maintains | $30.00 |
| Apr 2, 2026 | Evercore ISI Group | Maneka Mirchandaney | Outperform | Maintains | $32.00 |
| Mar 31, 2026 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $20.00 |
| Mar 31, 2026 | Goldman Sachs | Richard Law | Buy | Maintains | $36.00 |
| Mar 31, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $37.00 |
| Mar 31, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $22.00 |
| Mar 30, 2026 | Needham | Serge Belanger | Buy | Maintains | $32.00 |
| Mar 11, 2026 | Wedbush | Laura Chico | Outperform | Reiterates | $44.00 |
| Feb 27, 2026 | RBC Capital | Lisa Walter | Outperform | Maintains | $42.00 |
| Feb 4, 2026 | Needham | Serge Belanger | Buy | Reiterates | $42.00 |
| Feb 3, 2026 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $29.00 |
| Jan 8, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $40.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Initiates | $50.00 |
| Dec 23, 2025 | Needham | Serge Belanger | Buy | Maintains | $42.00 |
| Dec 10, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $47.00 |
| Dec 3, 2025 | William Blair | Lachlan Brown | Outperform | Initiates | $N/A |
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Initiates | $41.00 |
Viridian Therapeutics Inc. (VRDN) Competitors
The following stocks are similar to Viridian based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Viridian Therapeutics Inc. (VRDN) Financial Data
Viridian Therapeutics Inc. has a market capitalization of $1.47B with a P/E ratio of -4.3x. The company generates $70.85M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +83.3% quarter-over-quarter, while maintaining an operating margin of -95,643.2% and return on equity of -49.2%.
Valuation Metrics
Market Cap
$1.47B
Enterprise Value
$810.39M
P/E Ratio
-4.3x
PEG Ratio
-0.1x
Price/Sales
20.8x
Growth & Margins
Revenue Growth (YoY)
+83.3%
Gross Margin
N/A
Operating Margin
-95,643.2%
Net Margin
0.0%
EPS Growth
+83.3%
Financial Health
Cash/Price Ratio
+59.9%
Current Ratio
12.6x
Debt/Equity
7.3x
ROE
-49.2%
ROA
-27.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Viridian Therapeutics Inc. (VRDN) Business Model
About Viridian Therapeutics Inc.
What They Do
Develops innovative therapies for autoimmune diseases.
Business Model
Viridian Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of advanced medicines for autoimmune and rare diseases. The company earns revenue primarily through the development of its therapeutic candidates, which are in various stages of clinical trials, including Phase 3 for its lead programs targeting thyroid eye disease.
Additional Information
Founded in 2006 and headquartered in Waltham, Massachusetts, Viridian Therapeutics is actively advancing several programs, including a humanized monoclonal antibody and next-generation therapies for thyroid eye disease, while also exploring treatments for other autoimmune conditions. The company's expertise in antibody discovery and protein engineering positions it well to meet unmet medical needs in this niche market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
252
CEO
Mr. Stephen F. Mahoney J.D., MBA
Country
United States
IPO Year
2021
Website
www.viridiantherapeutics.comViridian Therapeutics Inc. (VRDN) Latest News & Analysis
Latest News
Quick Summary
The Phase 3 TEPEZZA OBI trial achieved its primary endpoint, reporting a 77% proptosis response rate in participants over 24 weeks compared to a placebo.
Why It Matters
The successful Phase 3 TEPEZZA trial signals strong market potential and effectiveness for the drug, likely boosting the company's stock value and investor confidence.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Amgen reported positive Phase 3 trial results for a new thyroid eye disease treatment, while Viridian Therapeutics is also developing a treatment for the condition.
Why It Matters
Amgen's positive trial results may enhance its market position and investor confidence, while Viridian could face increased pressure to deliver competitive results, impacting its stock performance.
Source: Barrons
Market Sentiment:
Negative
Quick Summary
Viridian Therapeutics (VRDN) announced positive topline results from its Phase III trial of Elegrobart for active thyroid eye disease, indicating potential advancement in treatment options.
Why It Matters
Positive trial results from Viridian Therapeutics boost confidence in its drug pipeline, potentially increasing stock value and attracting investor interest in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Viridian Therapeutics stock fell sharply after final-phase results for its thyroid eye disease treatment were deemed "positive, but lackluster."
Why It Matters
Viridian Therapeutics' stock decline signals investor disappointment in clinical trial results, potentially affecting future funding, market confidence, and overall valuation.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Viridian Therapeutics (NASDAQ:VRDN) shares dropped over 30% after the REVEAL-1 trial results for elegrobart in treating active thyroid eye disease met its primary endpoint.
Why It Matters
Viridian Therapeutics' stock drop reflects market reaction to trial results. Despite meeting primary endpoints, the significant decline may indicate investor concerns about future performance or competition.
Source: Proactive Investors
Market Sentiment:
Negative
Quick Summary
The REVEAL-1 trial for elegrobart met its primary endpoint, showing 54% and 63% responder rates for Q4W and Q8W dosing, respectively, versus 18% for placebo at week 24.
Why It Matters
The positive REVEAL-1 trial results for elegrobart indicate strong efficacy, likely boosting investor confidence and interest in the company's stock and future market potential.
Source: Benzinga
Market Sentiment:
Negative
Frequently Asked Questions About VRDN Stock
What is Viridian Therapeutics Inc.'s (VRDN) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Viridian Therapeutics Inc. (VRDN) has a median price target of $31.50. The highest price target is $50.00 and the lowest is $20.00.
Is VRDN stock a good investment in 2026?
According to current analyst ratings, VRDN has 16 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRDN stock?
Wall Street analysts predict VRDN stock could reach $31.50 in the next 12 months. This represents a 120.6% increase from the current price of $14.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viridian Therapeutics Inc.'s business model?
Viridian Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of advanced medicines for autoimmune and rare diseases. The company earns revenue primarily through the development of its therapeutic candidates, which are in various stages of clinical trials, including Phase 3 for its lead programs targeting thyroid eye disease.
What is the highest forecasted price for VRDN Viridian Therapeutics Inc.?
The highest price target for VRDN is $50.00 from Michael Yee at UBS, which represents a 250.1% increase from the current price of $14.28.
What is the lowest forecasted price for VRDN Viridian Therapeutics Inc.?
The lowest price target for VRDN is $20.00 from Derek Archila at Wells Fargo, which represents a 40.1% increase from the current price of $14.28.
What is the overall VRDN consensus from analysts for Viridian Therapeutics Inc.?
The overall analyst consensus for VRDN is bullish. Out of 22 Wall Street analysts, 16 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $31.50.
How accurate are VRDN stock price projections?
Stock price projections, including those for Viridian Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 4:06 AM UTC